Entity

Time filter

Source Type

St. Louis, MO, United States

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37 C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37 C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37 C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37 C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including


Patent
SEQUOIA science INC. | Date: 2012-10-11

Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.

Discover hidden collaborations